Rewritten Introduction for STS2026-21100

from reportlab.lib.pagesizes import A4
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.lib.units import cm, mm
from reportlab.lib.enums import TA_JUSTIFY, TA_CENTER, TA_LEFT
from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, HRFlowable, ListFlowable, ListItem
from reportlab.lib import colors
from reportlab.pdfbase import pdfmetrics
from reportlab.pdfbase.ttfonts import TTFont
import os

OUTPUT = "/home/daytona/workspace/icmr-proposal/STS2026-21100_Corrected_Proposal.pdf"

doc = SimpleDocTemplate(
    OUTPUT,
    pagesize=A4,
    rightMargin=2.5*cm,
    leftMargin=2.5*cm,
    topMargin=2.5*cm,
    bottomMargin=2.5*cm,
)

# ── Styles ──────────────────────────────────────────────────────────────────
W = A4[0] - 5*cm  # usable width

normal = ParagraphStyle(
    "normal",
    fontName="Times-Roman",
    fontSize=12,
    leading=14.4,        # single spacing ≈ 1.2× font size
    alignment=TA_JUSTIFY,
    spaceAfter=6,
)
bold_normal = ParagraphStyle(
    "bold_normal",
    fontName="Times-Bold",
    fontSize=12,
    leading=14.4,
    alignment=TA_JUSTIFY,
    spaceAfter=4,
)
heading1 = ParagraphStyle(
    "heading1",
    fontName="Times-Bold",
    fontSize=13,
    leading=16,
    alignment=TA_LEFT,
    spaceBefore=10,
    spaceAfter=4,
    textColor=colors.HexColor("#000000"),
)
heading2 = ParagraphStyle(
    "heading2",
    fontName="Times-Bold",
    fontSize=12,
    leading=14.4,
    alignment=TA_LEFT,
    spaceBefore=8,
    spaceAfter=3,
    underlineWidth=0,
)
center_bold = ParagraphStyle(
    "center_bold",
    fontName="Times-Bold",
    fontSize=13,
    leading=16,
    alignment=TA_CENTER,
    spaceAfter=4,
)
center_normal = ParagraphStyle(
    "center_normal",
    fontName="Times-Roman",
    fontSize=12,
    leading=14.4,
    alignment=TA_CENTER,
    spaceAfter=6,
)
ref_style = ParagraphStyle(
    "ref_style",
    fontName="Times-Roman",
    fontSize=11,
    leading=13,
    alignment=TA_JUSTIFY,
    spaceAfter=4,
    leftIndent=14,
    firstLineIndent=-14,
)
bullet_style = ParagraphStyle(
    "bullet_style",
    fontName="Times-Roman",
    fontSize=12,
    leading=14.4,
    alignment=TA_JUSTIFY,
    spaceAfter=3,
    leftIndent=18,
    firstLineIndent=-12,
)
italic_normal = ParagraphStyle(
    "italic_normal",
    fontName="Times-Italic",
    fontSize=12,
    leading=14.4,
    alignment=TA_JUSTIFY,
    spaceAfter=6,
)

def H1(text):
    return Paragraph(text, heading1)

def H2(text):
    return Paragraph(text, heading2)

def P(text):
    return Paragraph(text, normal)

def PB(text):
    return Paragraph(text, bold_normal)

def PI(text):
    return Paragraph(text, italic_normal)

def B(text):
    """Bullet point"""
    return Paragraph(f"\u2022\u2002{text}", bullet_style)

def SP(n=6):
    return Spacer(1, n)

def HR():
    return HRFlowable(width="100%", thickness=0.5, color=colors.black, spaceAfter=6, spaceBefore=6)

# ════════════════════════════════════════════════════════════════════════════
# CONTENT
# ════════════════════════════════════════════════════════════════════════════
story = []

# ── Header ──────────────────────────────────────────────────────────────────
story.append(Paragraph("STS2026-21100", ParagraphStyle("refid", fontName="Times-Bold", fontSize=11, alignment=TA_LEFT, spaceAfter=2)))
story.append(HR())
story.append(SP(4))

story.append(Paragraph("TITLE", center_bold))
story.append(Paragraph(
    "Plasma Levels of HSP90 in Adult Sickle Cell Disease Patients during "
    "Vaso-Occlusive Crisis versus Steady State: A Prospective Paired Study",
    center_normal))
story.append(HR())
story.append(SP(6))

# ── INTRODUCTION ────────────────────────────────────────────────────────────
story.append(H1("INTRODUCTION"))

story.append(P(
    "Sickle Cell Disease (SCD) is an autosomal recessive hemoglobinopathy caused by a Glu6Val "
    "point mutation in the beta-globin gene, producing abnormal haemoglobin S (HbS). Under "
    "deoxygenation, HbS polymerises, deforming erythrocytes into rigid sickle shapes and triggering "
    "haemolytic anaemia, recurrent vaso-occlusive crises (VOC), and progressive end-organ damage [1,2]. "
    "India bears the third highest global SCD birth rate, with prevalence reaching up to 40% in tribal "
    "communities across Central and Western India [3,4]. The Government of India\u2019s National Sickle "
    "Cell Anaemia Elimination Mission (2023) underscores SCD as a direct national priority, making "
    "research in this population both timely and policy-relevant."
))

story.append(P(
    "VOC is the leading cause of hospitalisation in SCD. It is now understood not merely as mechanical "
    "obstruction, but as a complex endovascular inflammatory event driven by P-selectin-mediated adhesion "
    "of sickle erythrocytes to activated endothelium, neutrophil-platelet interactions, and intravascular "
    "haemolysis that depletes nitric oxide (NO) and generates reactive oxygen species, perpetuating "
    "ischaemia-reperfusion injury and systemic inflammation [5,6]. Despite this mechanistic understanding, "
    "objective biomarkers capable of quantifying endovascular stress during VOC versus steady state "
    "remain a critical unmet need in clinical practice."
))

story.append(P(
    "Heat Shock Protein 90 (HSP90) is a conserved molecular chaperone constituting ~1\u20132% of total "
    "cellular protein, markedly induced by hypoxia, oxidative stress, and ischaemia-reperfusion injury [7,8,9]. "
    "Under physiological conditions, HSP90 couples with eNOS to sustain protective NO production, "
    "inhibiting adhesion and vasoconstriction. During VOC, oxidative stress uncouples this HSP90-eNOS "
    "complex, diverting enzymatic output toward pro-oxidant superoxide, amplifying endothelial dysfunction "
    "and the inflammatory cascade [13,14]."
))

story.append(P(
    "No published study has directly quantified plasma HSP90 levels during VOC versus steady state in "
    "SCD, and Indian patient data is entirely absent from the literature. This study proposes to compare "
    "plasma HSP90 levels in adult HbSS patients during acute VOC and steady state using a paired design, "
    "correlating findings with CBC, LDH, CRP, LFT, and RFT, to evaluate HSP90 as a potential "
    "stress-responsive endovascular biomarker in SCD."
))

story.append(SP(4))

# ── OBJECTIVES ──────────────────────────────────────────────────────────────
story.append(H1("OBJECTIVES"))

story.append(PB("Primary Objective:"))
story.append(P(
    "To evaluate and compare quantitative plasma levels of Heat Shock Protein 90 (HSP90) in adult "
    "patients with confirmed Sickle Cell Disease (HbSS) during an acute Vaso-Occlusive Crisis (VOC) "
    "versus their baseline Steady State."
))

story.append(PB("Secondary Objective:"))
story.append(P(
    "To correlate plasma HSP90 levels with haematological parameters (Complete Blood Count) and "
    "biochemical markers \u2014 Lactate Dehydrogenase (LDH), C-Reactive Protein (CRP), Liver Function "
    "Tests (LFT), and Renal Function Tests (RFT) \u2014 during both Vaso-Occlusive Crisis and Steady State."
))

story.append(PB("Hypothesis:"))
story.append(PI(
    "Plasma HSP90 levels are significantly elevated during acute VOC compared to steady state in adult "
    "HbSS patients, reflecting heightened cellular stress and eNOS uncoupling, and will correlate "
    "positively with markers of haemolysis and inflammation."
))

story.append(SP(4))

# ── METHODOLOGY ─────────────────────────────────────────────────────────────
story.append(H1("METHODOLOGY"))

story.append(H2("Study Design"))
story.append(P("Prospective Paired Observational Study."))

story.append(H2("Study Centre"))
story.append(P(
    "Department of Medicine, a tertiary care sickle cell referral centre in Central India."
))

story.append(H2("Study Population"))
story.append(P(
    "Confirmed Sickle Cell Disease (HbSS by HPLC) patients admitted with an acute vaso-occlusive "
    "crisis. Each participant will serve as their own control and will be reassessed after 3 weeks "
    "during steady state."
))

story.append(H2("Inclusion Criteria"))
story.append(B("Confirmed SCD patients (HbSS genotype) of either sex, aged 18\u201355 years."))
story.append(B(
    "<b>Group A \u2013 Vaso-Occlusive Crisis:</b> Patients presenting with acute severe pain attributable "
    "to VOC for \u22654 hours, confirmed by the treating clinician, with no alternate cause of pain "
    "identified, within 24 hours of crisis onset."
))
story.append(B(
    "<b>Group B \u2013 Steady State:</b> Patients who are asymptomatic, with no acute episode requiring "
    "hospitalisation for at least 4 consecutive weeks prior to sample collection, with no blood "
    "transfusion in the preceding 3 months."
))
story.append(B("Willingness to provide written informed consent."))

story.append(H2("Exclusion Criteria"))
story.append(B("Patients with HbSC, HbS/\u03b2-thalassaemia, or other compound heterozygous genotypes."))
story.append(B("Patients who have received blood transfusion within 3 months prior to sample collection."))
story.append(B(
    "Patients with known malignancy, chronic inflammatory disorders, concurrent febrile illness, "
    "sepsis, or active infection at time of sample collection."
))
story.append(B("Pregnant patients."))
story.append(B(
    "Patients who fail to attain steady state at 3-week follow-up due to persistent VOC, acute chest "
    "syndrome, infection, or hospitalisation."
))
story.append(B("Patients unwilling to provide the second blood sample or lost to follow-up."))

story.append(H2("Sample Size"))
story.append(P(
    "Sample size was calculated using the paired Cohen\u2019s d formula. In the absence of prior "
    "Indian data on plasma HSP90 in SCD, a moderate effect size (Cohen\u2019s d\u202f=\u202f0.5) was assumed, "
    "consistent with paired biomarker studies in similar inflammatory conditions. Using Z\u03b1/2\u202f=\u202f1.96 "
    "(95% CI) and Z\u03b2\u202f=\u202f0.84 (80% power), the calculated sample size is 32 participants. "
    "Adding a 20% non-response rate, the final sample size is <b>40 participants</b>, each providing "
    "two samples (VOC and steady state), yielding 80 samples for analysis."
))

story.append(H2("Sampling Technique"))
story.append(P(
    "Consecutive sampling: all eligible HbSS patients admitted with acute VOC during the study "
    "period will be enrolled until the required sample size of 40 is achieved."
))

story.append(H2("Sample Collection"))
for item in [
    "Written informed consent will be obtained before sample collection.",
    "5 mL venous blood collected via sterile venipuncture: 2 mL in K3-EDTA tube for CBC analysis; "
    "3 mL in clot activator tube, centrifuged at 3000 rpm for 10 minutes at 4\u00b0C for HSP90 analysis.",
    "Plasma will be aliquoted and stored at \u221280\u00b0C until analysis.",
    "Samples will be transported immediately to the Biochemistry laboratory under cold-chain conditions.",
]:
    story.append(B(item))

story.append(H2("Laboratory Methodology"))
for item in [
    "Plasma samples stored at \u221280\u00b0C will be thawed at room temperature and mixed gently before analysis. A maximum of 2 freeze-thaw cycles will be permitted.",
    "Plasma HSP90 levels will be quantified using a commercially available human HSP90 sandwich ELISA kit, following the manufacturer\u2019s instructions.",
    "Standards, controls, and samples will be run in duplicate in wells pre-coated with anti-HSP90 capture antibody and incubated at 37\u00b0C for 90 minutes.",
    "After washing, biotinylated detection antibody (37\u00b0C, 60 min) and streptavidin-HRP conjugate (37\u00b0C, 30 min) will be added sequentially with appropriate wash steps.",
    "TMB substrate will be used for colour development; the reaction will be stopped with 2N H\u2082SO\u2084.",
    "Optical density will be measured at 450 nm using a calibrated microplate reader.",
    "Plasma HSP90 concentrations (ng/mL) will be calculated using a 4-parameter logistic (4PL) standard curve.",
    "Ancillary investigations: CBC (automated haematology analyser on EDTA sample); serum LDH, CRP, LFT, and RFT as markers of haemolysis, inflammation, and organ function.",
    "All procedures will be performed under standard biosafety conditions (BSL-2 norms).",
]:
    story.append(B(item))

story.append(H2("Data Collection"))
story.append(P(
    "After obtaining informed consent, required clinical and laboratory data will be recorded in a "
    "predesigned Case Report Form (CRF). Questionnaire, Patient Information Sheet, and Informed "
    "Consent Form (blank formats, English only, no identifying information) are attached."
))

story.append(H2("Statistical Analysis"))
story.append(P(
    "Data will be entered in MS Excel and analysed using SPSS v26.0. Categorical variables will be "
    "expressed as frequencies and percentages; quantitative variables as mean \u00b1 SD or median (IQR). "
    "Plasma HSP90 levels between VOC and steady state will be compared using the paired Student\u2019s "
    "t-test or Wilcoxon signed-rank test. Correlations will be assessed using Pearson\u2019s or "
    "Spearman\u2019s coefficients. ROC analysis will assess discriminatory ability. A p-value <0.05 "
    "will be considered statistically significant."
))

story.append(H2("Study Duration"))
story.append(P("6 months from the date of IEC approval."))

story.append(H2("Quality Assurance"))
for item in [
    "Plasma HSP90 will be measured using a validated commercial ELISA kit with positive and negative controls included in every run.",
    "Duplicate sample coefficient of variation (CV) will be maintained below 10%; assays exceeding this limit will be repeated.",
    "Haematological and biochemical investigations will be performed using standardised automated analysers with regular calibration.",
    "All laboratory procedures will follow institutional standard operating procedures for sample handling and analysis.",
]:
    story.append(B(item))

story.append(H2("Ethical Considerations"))
story.append(P(
    "IEC approval will be obtained from the Institutional Ethics Committee prior to commencement of "
    "research. The study will adhere to the principles of the Declaration of Helsinki and the ICMR "
    "National Ethical Guidelines for Biomedical and Health Research involving Human Participants, "
    "2017. Written informed consent will be obtained from all participants. All identifying "
    "information will be kept strictly confidential and will not be disclosed."
))

story.append(SP(4))

# ── IMPLICATIONS / OUTCOME ──────────────────────────────────────────────────
story.append(H1("IMPLICATIONS / STUDY OUTCOME"))

story.append(P(
    "This study will generate the first Indian data on plasma HSP90 levels in adult SCD patients "
    "during VOC and steady state, directly addressing a gap in the existing literature. Findings will "
    "provide preliminary evidence for HSP90 as a stress-responsive endovascular biomarker, with "
    "potential utility in objective disease monitoring and prognostication. Correlation with established "
    "haematological and biochemical parameters will contextualise its biological significance. The "
    "results will contribute to India\u2019s National Sickle Cell Anaemia Elimination Mission by "
    "identifying molecular targets for future therapeutic research and informing evidence-based "
    "management protocols for VOC in Indian patients."
))

story.append(SP(4))

# ── REFERENCES ───────────────────────────────────────────────────────────────
story.append(H1("REFERENCES"))
story.append(PI("(Vancouver style \u2013 PubMed-indexed articles only)"))
story.append(SP(4))

refs = [
    "Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376(16):1561\u20131573.",
    "Thomson AM, McHugh TA, Oron AP, et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000\u20132021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585\u2013e599.",
    "Colombatti R, Hegemann I, Medici M, Birkeg\u00e5rd C. Systematic literature review shows gaps in data on global prevalence and birth prevalence of sickle cell disease and sickle cell trait. J Clin Med. 2023;12(17):5538.",
    "Gupta K, Krishnamurti L, Jain D. Sickle cell disease in India: the journey and hope for the future. Hematology. 2024;2024(1):1\u20139.",
    "Quinn CT. Sickle cell disease in childhood: from newborn screening through transition to adult medical care. Pediatr Clin North Am. 2013;60(6):1363\u20131381.",
    "Darbari DS, Sheehan VA, Ballas SK. The vaso-occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management. Eur J Haematol. 2020;105(3):237\u2013246.",
    "Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019;14:263\u2013292.",
    "Schopf FH, Biebl MM, Buchner J. The HSP90 chaperone machinery. Nat Rev Mol Cell Biol. 2017;18(6):345\u2013360.",
    "Csermely P, Schnaider T, Soti C, Proh\u00e1szka Z, Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. Pharmacol Ther. 1998;79(2):129\u2013168.",
    "Kregel KC. Invited review: heat shock proteins: modifying factors in physiological stress responses and acquired thermotolerance. J Appl Physiol. 2002;92(5):2177\u20132186.",
    "Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol. 2010;11(7):515\u2013528.",
    "Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5(10):761\u2013772.",
    "Garc\u00eda-Carde\u00f1a G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature. 1998;392(6678):821\u2013824.",
    "Hebbel RP, Vercellotti GM. Multiple inducers of endothelial NOS (eNOS) dysfunction in sickle cell disease. Am J Hematol. 2021;96(11):1505\u20131517.",
]

for i, ref in enumerate(refs, 1):
    story.append(Paragraph(f"{i}.\u2002{ref}", ref_style))

# ── Build PDF ────────────────────────────────────────────────────────────────
doc.build(story)
print(f"PDF created: {OUTPUT}")